Of the many hidden gems in the Affordable Care Act, one of my favorites is Physician Compare. This website could end up being a game changer—holding doctors accountable for their care and giving consumers a new way to compare and choose doctors. Or it could end up a dud.
The outcome depends on how brave and resolute the Centers for Medicare and Medicaid Services (CMS) is over the next few years. That’s because the physician lobby has been less than thrilled with Physician Compare, and, for that matter, with every other effort to publically report measures of physician performance and quality.
I’d give CMS a C+ to date. Not bad considering it’s the tough task. The agency has been cautious and deliberate. But after the many problems with Hospital Compare, Nursing Home Compare, Home Health Compare, and Dialysis Facility Compare—not to mention the shadow of healthcare.gov’s initial rollout—that’s understandable. They want, I hope, to get this one right from the get-go. And competition from the private sector looms.
Continue reading “What’s Next For Physician Compare?”
Filed Under: THCB
Tagged: CMS, Healthcare.gov, Physician Compare
Jan 23, 2015
Omnibus Bill Impacts HIT
The 2015 federal budget includes about $60.4 million for the ONC, which is less than the $75 million requested and on par with the 2014 budget. Congress allocated an additional $38.8 million to the HHS Office for Civil Rights, the agency that enforces HIPAA. Also in the bill: a controversial requirement for the ONC to decertify products that block health information sharing.
Appalling Meaningful Use Penalties
CMS reports that more than 257,000 eligible professionals will face penalties in 2015 for failing to meet Meaningful Use requirements. The AMA quickly announced it was “appalled by the news.”
Another Call to Cut Reporting Period
A group of 30 Republican House members call on HHS to shorten the 2015 Meaningful Use reporting period from 365 days to 90 days. A number of professional groups, including the AAFP and CHIME, support the extension.
From Foes to Financiers
Former Allscripts executives Glen Tullman and Lee Shapiro invest in Lightbeam Health Solutions, a population health management solution provider. Pat Cline, the founder and former president of NextGen, is currently Lightbeam’s CEO.
ATA Offers Accreditation
The American Telemedicine Association launches an accreditation program for providers offering online, real-time consults to patients.
Continue reading “HIT Newser: Appalling Meaningful Use Penalties”
Filed Under: Uncategorized
Tagged: AMA, CMS, HIT Newser, HITNewser, Meaningful Use
Dec 23, 2014
CMS Gives Hospitals One Month Attestation Reprieve
CMS extends the deadline for eligible hospitals and critical access hospitals to attest for MU from November 30 to December 31, giving hospitals more time to submit MU data for the 2014 program year in order to receive payments under EHR incentive programs. CMS also pushed back the deadline for hospitals to electronically submit clinical quality measures to December 31.
VA Issues RFP for New Scheduling System
The VA issues an RFP to replace its 30 year-old appointment scheduling system with a commercially available solution to integrate with its existing VistA platform. The proposal deadline is January 9 and potential bidders will not be required to have prior experience working with the agency.
CareTech Solutions Negotiating Sale to HTC Global Services
HIT service provider CareTech Solutions files an “intent to sell” to HTC Global Services, a provider of IT services for multiple industries. Continue reading “HIT Newser: Alarm Issues Top Health Hazard List”
Filed Under: THCB
Tagged: CMS, HIT Newser, Practice Fusion, USDA, VA
Dec 1, 2014
A No Way for Allscripts and MyWay
A North Carolina arbitration panel rules that Allscripts must pay Etransmedia $9.7 million for a breach of their partner agreement in violation of the state’s Unfair and Deceptive Trade Practices Act. The panel found that Allscripts unfairly profited by inducing Etransmedia to buy MyWay software licenses and assuring Etransmedia that it would make the product Meaningful Use-compliant. Allscripts later announced that rather than update MyWay it would phase out the product, leading the panel to rule that Allscripts “deliberately sabotaged” Etransmedia’s sales efforts.
The recent Republican sweep of the House and Senate may bode well for health IT, predict several industry pundits. One issue that will likely be discussed: the reduction of Stage 2 MU reporting requirements from 365 days to 90 days. Also look for renewed interest in issues around interoperability, telemedicine, and regulation of medical devices, software, and mobile apps.
Stage 2 Attestations Numbers: Disappointing but Predictable
CMS reports that only 4,656 EPs and 258 hospitals have attested for Stage 2 MU through the end of September. That’s less than 17% of the nation’s hospitals and a mere two percent of EPs (though EPs have until the end of February to report their progress.) Officials from the AMA, CHIME, HIMSS, and MGMA called the results disappointing yet predictable, and renewed calls for a shortened MU reporting period in 2015 and more program flexibility. Continue reading “Health IT Newser”
Filed Under: THCB
Tagged: CHIME, CMS, Meaningful Use Stage II, MyWay
Nov 10, 2014
One of the big questions since the inception of the Medicare Shared Savings Program has been whether the model would only work in regions with extremely high baseline costs. Farzad’s state-level analysis of earlier MSSP results suggested that ACOs in higher-cost areas were more likely to receive shared savings. It’s one of the questions that Bob Kocher and Farzad received in the wake of the op-ed on Rio Grande Valley Health Providers last week.
So we decided to dig into the data.
We’re still waiting for CMS to make baseline costs for ACOs – and the local areas they serve – public. But in the meantime, we linked each ACO to a Hospital Referral Region using the main ACO address provided by CMS – and took a look at the region’s per capita Medicare costs as a predictor of ACO success.
Continue reading “Why ACO Savings Aren’t About Location.”
Filed Under: Tech, THCB
Tagged: ACOs, CMS, Medicare Shared Savings Program, Rio Grande Valley
Oct 8, 2014
If the federal government’s new Open Payments website were a consumer product, it would be returned to the manufacturer for a full refund.
Open Payments is the government’s site for publishing payments made to doctors and teaching hospitals by drug and medical device manufacturers. It includes 4.4 million payments, worth $3.5 billion, to more than half a million doctors and almost 1,360 teaching hospitals.
In a news release announcing the site’s launch, the Centers for Medicare and Medicaid Services said the goal is “to help consumers understand the financial relationships between the health care industry, and physicians and teaching hospitals.”
Continue reading “Government’s New Doctor Payments Website Worthy of a Recall”
Filed Under: Tech, THCB
Tagged: CMS, open data, Open Payments, ProPublica
Oct 1, 2014
CMS recently announced another change to health IT policy in order to offer healthcare providers greater flexibility. But what will the unintended consequences of this latest change be?
Over the Labor Day weekend, CMS announced that the Meaningful Use Stage 2 deadline will be extended through 2016 in order to offer more options and greater flexibility to providers for the certified use of EHRs. In the interest of full disclosure, I found the timing to be strange— a rule published over a holiday weekend seems an odd choice, particularly when it is being touted as a benefit to the industry and the impact on healthcare provider organizations and clinicians, alike, is monumental.
Unfortunately, I think the additional flexibility allotted by this rule is the latest example of the unintended consequences of health IT regulations. In an effort to make things easier and give healthcare providers more leeway, they have, in fact, made the situation unnecessarily more complex.
Agility is not healthcare’s strong suit
It seems at this point, too many options, or waffling between them (for instance the new ICD-10 transition deadline), can be more crippling than stringent regulations, particularly when there is so much on the line. Healthcare organizations don’t have the wherewithal to vacillate with implementations; they are wrestling with string-tight budgets and constantly shifting rules require large cultural and behavioral changes. As a result, as Dr. John Halamka noted, health IT agendas are being constantly hijacked by regulatory changes, such as Meaningful Use and ICD-10.
It now seems that hospital administrative teams and physicians again must endure constantly shifting rules that they’ve been coping with for years under Meaningful Use. As Dr. Ben Kanter, former CMIO of Palomar Health, so astutely noted “A computer system is a tool, just as a scalpel is a tool. What if a surgeon’s scalpel changed every few weeks? How is it possible to deliver good care if the primary tool you are using keeps changing on an irregular basis?” Continue reading “Sometimes the Best Choice is the Simplest One”
Filed Under: THCB
Tagged: Certification, CMS, EHR, ICD-10, Meaningful Use Stage 2, Washington
Sep 5, 2014
“Drugs don’t work in people who don’t take them.” C. Everett Koop, former US Surgeon General
Cost-based non-adherence, like any lack of medication adherence, leads to further complications and hospitalizations that could have been prevented. CMS appears to have recognized this when they announced that a new ACO measures on whether “providers have educated patients about the cost of medications” in the 2015 fee schedule. Cost and quality conversations between doctors and patients are becoming a cornerstone to value-based care.
The most expensive drugs are the ones that the patient never takes. Nearly one third of prescriptions go unfilled. When patients cannot afford a medication, and only discover the price or out-of-pocket cost at the prescription counter, it’s a big risk to long-term outcomes.
“It has been well established that a lack of affordability can drive a lack of adherence to a course of medications. Patients who do not take their medications cost the U.S. healthcare system an estimated $300 billion in avoidable medical spending annually due to poorer health, more frequent hospitalizations and a higher risk of mortality”, according to The Center for Health Value Innovation and the Network for Health Value in Innovation.
A lack of medication adherence drives further costs for the system and suffering for patients. Estimates are that more than a third of medicine-related hospitalizations happen because people did not take medicine as directed, leading to over 125,000 deaths.
Medication non-adherence, of course, can have many reasons: side effects, difficulty in administering the drug, and others, but there is clear evidence that cost is a factor driving non-adherence. 27% of Americans did not fulfill a prescription due to financial hardship in 2012 according to a Kaiser Family Survey. As copays, deductibles and out-of-pocket expenses go up, so, likely, will non-adherence, and value-based care, and value-based benefits must understand the costs related to non-adherence.
Continue reading “The Cost-Response Curve”
Filed Under: Economics, THCB
Tagged: ACOs, CMS, Cost, Cost-Response Curve, Coumadin, does-response, Efficacy, Non-adherence, RxREVU
Jul 11, 2014
Adverse events – when bad things happen to patients because of what we as medical professionals do – are a leading cause of suffering and death in the U.S. and globally. Indeed, as I have written before, patient safety is a major issue in American healthcare, and one that has gotten far too little attention. Tens of thousands of Americans die needlessly because of preventable infections, medication errors, surgical mishaps, and so forth. As I wrote previously, according to Office of Inspector General (OIG), when an older American walks into a hospital, he or she has about a 1 in 4 chance of suffering some sort of injury during their stay. Many of these are debilitating, life-threatening, or even fatal. Things are not much better for younger Americans.
Given the magnitude of the problem, many of us have decried the surprising lack of attention and focus on this issue from policymakers. Well, things are changing – and while some of that change is good, some of it worries me. Congress, as part of the Affordable Care Act, required Centers for Medicare and Medicaid Services (CMS) to penalize hospitals that had high rates of “HACs” – Hospital Acquired Conditions. CMS has done the best it can, putting together a combination of infections (as identified through clinical surveillance and reported to the CDC) and other complications (as identified through the Patient Safety Indicators, or PSIs). PSIs are useful – they use algorithms to identify complications coded in the billing data that hospitals send to CMS. However, there are three potential problems with PSIs: hospitals vary in how hard they look for complications, they vary in how diligently they code complications, and finally, although PSIs are risk-adjusted, their risk-adjustment is not very good — and sicker patients generally have more complications.
So, HACs are imperfect – but the bottom line is, every metric is imperfect. Are HACs particularly imperfect? Are the problems with HACs worse than with other measures? I think we have some reason to be concerned.
Continue reading “Penalizing Hospitals For Being Unsafe”
Filed Under: Tech, THCB
Tagged: Adverse Events, CMS, hospital acquired conditions (HACs), Meaningful Use, To Err is Human
Jun 23, 2014
When CMS approved Solvadi, Gilead’s $84,000 drug for hepatitis C, the stakes were raised in drug price wars. Two opposing forces, one, a financial push toward lower costs came up against an opposing force of public sentiment. The FDA’s goal of getting 90% of patients moved from costly branded prescriptions to generics met with an an large outcry in social and traditional media for providing the best available care, rallying around the story of a patient. The wave of sentiment seems to have won over CMS.
Granted, CMS was likely considering the reversal in its policy on Solvadi, but it was the May 12th coverage by the Kaiser Family Foundation and NPR of the patient who was denied treatment, and the amplification across social media that turned the tide toward coverage.
Solvadi had not been approved by the patient’s prescription drug carrier, so physicians lobbied CMS for coverage of Solvadi and the life of the patient. Solvadi appears to cure liver cancer in 90% of the patients who take it as recommended. CMS agreed. As a single payer, they have the incentive to balance drug costs and benefits with other costs and benefits, and new therapies often win the fight for coverage.
Getting Covered: The decision to pay for drug combinations is often quicker than FDA approval of the drug combinations
Objective health policy observers such as KFF note that in the early days of successful antiviral drug treatment for HIV, payers allowed doctors to “mix and match” medications in “off-label” or unapproved combinations as they thought best. Medicare is often slow to approve the physician-driven cocktails, so getting CMS to adopt the strategy was a win for many very sick people in this country, as it sets a precedent for “exceptions.”
One doctor at Beth Israel Health System in Boston has a trial that has shown that combining Solvadi with another high-cost treatment, Olysio (by Janssen, cost $66,000 for a course of treatment) resulted in 90-100% cure rate.
The CMS statement in this case noted that that “the new policy will apply broadly to hepatitis C patients whose doctors prescribe the combined use of the two drugs because they meet certain criteria laid out in January by the Infectious Diseases Society of America and the American Association for the Study of Liver Diseases.” Those guidelines recommend the combined use of the two drugs in patients with advanced liver disease who have failed to be cured by earlier drug regimens – even though the FDA has not yet approved the combination—because Medicare guidelines say a patient must have access to a therapy if his or her condition warrants it.
Continue reading “What’s the Value of a Cancer Cure?”
Filed Under: THCB
Tagged: Cirrhosis, CMS, FDA, Hepatitis B, Hepatitis C, HIV, PhRMA, Solvadi, Value-Based Medicine, value-driven pharmaceuticals
Jun 21, 2014